Xin Wua, Ying Kanga, Jun Zhaoa, Huan Guoa, Yu Xieb, Xi Fenga, Xuan Dinga, Kun Leea 
Abstract
Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare type of acquired hemolytic anemia affecting all hematopoietic cell types. The abnormality of red blood cells in this disease predisposes to intravascular complement-mediated hemolysis. This study aimed to investigate PNH clone detection in pregnancy by the A fluorescein-labeled proaerolysin variant (FLAER) era. We have reviewed all pregnant and non-pregnant patients with a new diagnosis of PNH admitted between 2007 and 2014 in "First Affiliated Hospital of Xinjiang Medical University", China. Overall survival (OS) and event free survival (EFS) of the patients, and their relation with demographic and clinico-pathological factors have been analyzed.
Keywords: Paroxysmal Nocturnal Hemoglobinuria; Anemia; PNH; Hemolytic anemia
Copyright © 2015 by The American Society for BioMedicine and BM-Publisher, Inc.
1. Araten DJ, Nafa K, Pakdeesuwan K, et al. Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals. Proc Natl Acad Sci USA 1999; 96:5209–14. [PubMed]
2. Araten DJ, Swirsky D, Karadimitris A, et al. Cytogenetic and morphological abnormalities in paroxysmal nocturnal haemoglobinuria. Br J Haematol 2001; 115:360–8. [PubMed]
3. Bemba M, Guardiola P, Garderet L, et al. Bone marrow transplantation for paroxysmal nocturnal haemoglobinuria. Br J Haematol 1999;105:366–8. [PubMed]
4. Bourantas K. High-dose recombinant erythropoietin and low-dose corticosteroids for treatment of anemia in paroxysmal nocturnal hemoglobinuria. Acta Haematol 1994; 91:62–5. [PubMed]
5. Gargiulo L, Lastraioli S, Cerruti G, et al. Highly homologous T-cell receptor beta sequences support a common target for autoreactive T cells in most patients with paroxysmal nocturnal hemoglobinuria. Blood 2007; 109:5036–42. [PubMed]
6. Hill A, Hillmen P, Richards SJ, et al. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood 2005a; 106:2559–65. [PubMed]
7.Hill A, Richards SJ, Hillmen P. Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2007a; 137:181–92. [PubMed]
8. Hillmen P, Muus P, Duhrsen U, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 2007; 110:4123–8. [PubMed]
9. Hu R, Mukhina GL, Piantadosi S, et al. PIG-A mutations in normal hematopoiesis. Blood 2005; 105:3848–54. [PubMed]
10. Murakami Y, Kosaka H, Maeda Y, et al. Inefficient response of T lymphocytes to glycosylphosphatidylinositol anchor-negative cells: implications for paroxysmal nocturnal hemoglobinuria. Blood 2002; 100:4116–22. [PubMed]
11. Brodsky RA. Narrative review. Paroxysmal nocturnal hemoglobinuria: the physiology of complement-related hemolytic anemia. Ann Intern Med 2008; 148:587–595. [PubMed]
12. Parker CJ. Historical aspects of paroxysmal nocturnal haemoglobinuria: defining the disease. Br J Haematol 2002;117:3–22. [PubMed]
13.Parker C, Omine M, Richards S, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 2005; 106:3699–3709. [PubMed]
14. Rollins SA, Sims PJ. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. J Immunol 1990; 144:3478–3483. [PubMed]
15. de Latour RP, Mary JY, Salanoubat C, et al. Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. Blood 2008; 112:3099–3106. [PubMed]
16. Nishimura J, Kanakura Y, Ware RE, et al. Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine (Baltimore)2004; 83:193–207. [PubMed]
17. Dunn DE, Tanawattanacharoen P, Boccuni P, et al. Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes. Ann Intern Med 1999;131:401–408. [PubMed]
18. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 2006; 108:2509–2519. [PubMed]
19. Brodsky RA, Mukhina GL, Li S, et al. Improved detection and characterization of paroxysmal nocturnal hemoglobinuria using fluorescent aerolysin. Am J Clin Pathol 2000;114:459–466.. [PubMed]
20. Hu R, Mukhina GL, Piantadosi S, et al. PIG-A mutations in normal hematopoiesis. Blood 2005; 105:3848–3854. [PubMed]
21. Traulsen A, Pacheco JM, Dingli D. On the origin of multiple mutant clones in paroxysmal nocturnal hemoglobinuria. Stem Cells 2007; 25:3081–3084. [PubMed]
22. Matsui WH, Brodsky RA, Smith BD, Borowitz MJ, Jones RJ. Quantitative analysis of bone marrow CD34 cells in aplastic anemia and hypoplastic myelodysplastic syndromes. Leukemia 2006; 20:458–462. [PubMed]
23. Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006; 355:1233–1243. [PubMed]
24. Olteanu H, Xu Y. The use of flow cytometry in diagnosis of paroxysmal nocturnal hemoglobinuria. Lab Med. 2006; 37:498–502.
25. Gordon-Smith EC, Marsh JCW (2005) Acquired haemolytic anaemias. In: Hoffbrand AV, Catovsky D, Tuddenham EGD (eds) Postgraduate haematology, 5th edn. Blackwell Publishing, London, pp 151–168.
26. Petz LD. Cold autoimmune haemolytic anaemia. Blood Review 2008; 22:1–15. [PubMed]
27.Gertz MA. Management of cold haemolytic syndrome. Br J Haematol 2007; 138:422–429. [PubMed]
28. Bain BJ, Win N. Acquired haemolytic anaemias. In: Lewis M, Bain BJ, Bates I, editors. Dacie and Lewis Practical Haematology. 10. Mosby: Elsevier; 2006. pp. 239–270.
29. Dhingra S, Wiener JJ, Jackson H. Management of cold agglutinin immune hemolytic anemia in pregnancy. Obstet Gynecol 2007; 110(2 Pt 2):485–6. [PubMed]
30. Ray JG, Burows RF, Ginsberg JS, Burrows EA. Paroxysmal nocturnal hemoglobinuria and the risk of venous thrombosis: review and recommendations for management of the pregnant and nonpregnant patient. Haemostasis 2000; 30(3):103–117. [PubMed]
31. Van Bijnen STA, Van Heerde WL, Muus P. Mechanisms and clinical implications of thrombosis in paroxysmal nocturnal hemoglobinuria. J Thromb Haemost 2012; 10:1–10. [PubMed]
32. Hillmen P, Hall C, Marsh JC, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2004; 350:552–559. [PubMed]
33. Santarone S, Bacigalupo A, Risitano AM, et al. Hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria: long term results of a retrospective study on behalf of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Haematologica 2010; 95(6):983–988. [PubMed]
Limited access article
Purchase this article at rate $55.00 and received Full-Text/PDF
For any technique error please contact us and will be response to sending purchase article by email.
Thank you for visiting American Journal of BioMedicine. * = Required fields
[gravityform id=”6″ name=”Feedback”]
References
This article with limited access need to be buy, before continue with your purchase please read carefully the AJBM terms and conditions of purchase.
You will have online immediate access to article following the completion of this purchase and you may download and print a copy of each article for your personal use. Use the coding below to purchase your article as PDF by credit card, debit card, payball will be asked to supply your billing card information.
